Iovance Biotherapeutics, Inc.

This study tests whether adding a personalized cell therapy (lifileucel, made from a patient's own tumor-fighting immune cells) to the standard immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated yet. A…

This study tests a new drug (IOV-3001) that boosts the immune system, given together with a personalized cell therapy (lifileucel) in people with advanced melanoma that has stopped responding to standard treatments. About 42 adults with unresectable or metastatic melanoma will ta…

This study tests a treatment called lifileucel, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight advanced endometrial cancer. About 60 people who have already tried other treatments will receive this cell therapy. The main goal is to see if the tr…

This program offers a special cell therapy called AMTAGVI to people with advanced melanoma that cannot be removed by surgery or has spread. The treatment is made from the patient's own immune cells and is normally only given when it meets strict quality standards. Here, patients …

This study tests a new treatment called LN-145, which uses immune cells taken from a patient's own tumor to fight metastatic non-small-cell lung cancer. About 170 adults with stage IV lung cancer that has spread will receive these specially grown cells. The goal is to see if this…